IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: A protein consisting of the fragment A in combination with recombinant human IL-2 was successfully used to treat cutaneous T cell lymphoma, resulting in denileukin diftitox DAB389 becoming the first immunotoxin approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma.